title: [A controlled clinical trial of Consupren versus cyclophosphamide in chronic glomerulonephritis].
abstract: BACKGROUND
  Experience gained from recent studies shows, that Cyclosporine-A (Cy-A) may decrease proteinuria (PU) in some forms of chronic glomerulonephritis (GN) with the nephrotic syndrome. The aim of this study was to test the efficacy of Czech-made Cy-A, Consupren.
  
  
  RESULTS
  30 patients with chronic GN, confirmed by biopsy and PU higher than 3 g/d, corticodependent or corticoresistant, were randomized according to the month of birth to either therapy with Consupren at an initial dose of 5 mg/kg/d (CS group, after dropout of 3 patients who did not finish the treatment, n = 16) or Cyclophosphamide at a dose of 1.5 mg/kg/d (K group, n = 11), and prednisone maintained at the original dose in both groups. The treatment was stopped after six months or after achieving remission. The main criterion of efficacy was PU. The decrease in mean values, statistically evaluated by Holm's procedure was highly significant in the CS group and non-significant in the K group. A similar evaluation of PU corrected by glomerular filtration rate was significant in both groups. Partial or complete remission was reached in 50% of CS group patients and in 34% of K group patients (NS). In the CS group a significant increase in the mean values of albumin and gama-globulin, and a decrease in cholesterol levels were observed. In the K group, these changes were non-significant.
  
  
  CONCLUSIONS
  In patients with chronic GN and the nephrotic syndrome, the efficacy of Consupren treatment gives comparable, or even better results versus treatment with Cyclophosphamide.
authors.affiliation: Klinika nefrologie IKEM, Praha.
authors.forename: I
authors.initials: I
authors.lastname: Matl
authors.forename: K
authors.initials: K
authors.lastname: Matousovic
authors.forename: V
authors.initials: V
authors.lastname: Herout
authors.forename: K
authors.initials: K
authors.lastname: Konecný
authors.forename: A
authors.initials: A
authors.lastname: Kovác
authors.forename: I
authors.initials: I
authors.lastname: Rychlík
authors.forename: D
authors.initials: D
authors.lastname: Sobotová
authors.forename: R
authors.initials: R
authors.lastname: Roland
authors.forename: I
authors.initials: I
authors.lastname: Zdichyncová
authors.forename: V
authors.initials: V
authors.lastname: Lánská
mesh_terms: D000328:Adult; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide